Skip to main content
. 2020 Jun 11;12(6):542. doi: 10.3390/pharmaceutics12060542

Figure 6.

Figure 6

Production of CNS-targeted nanocarriers through microfluidic devices: (a) Tranferrin functionalized poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) for the treatment of HIV neuropathology, (b) siRNA-loaded lipid NPs produced with a staggered herringbone microfluidic mixer, intended to silence neuronal gene expression. Reprinted with permission from: (a) Martins et al. [19], (b) Rungta et al. [119].